Correction to: Lithium’s Gene Expression Profile, Relevance to Neuroprotection A cDNA Microarray Study (Cellular and Molecular Neurobiology, (2013), 33, 3, (411-420), 10.1007/s10571-013-9907-x);Lithium's gene expression profile, relevance to neuroprotection A cDNA microarray study

Cellular and Molecular Neurobiology

Volumn 33, Issue 3, 2013, Pages 411-420

  Farah, Raymond ^a,d   Khamisy Farah, Rola ^b   Amit, Tamar ^c   Youdim, Moussa B H ^c   Arraf, Zaher ^c  

^a BAR ILAN UNIVERSITY   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Rebecca Sieff Government Hospital   (Israel)

Author keywords

cDNA microarray; CREB; ERK1; Gene expression profile; Lithium; MAP kinase; MPTP; PKC; Reverse transcription

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE 5; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GLUTATHIONE PEROXIDASE 3; INHIBIN A; INTERFERON REGULATORY FACTOR; LITHIUM CHLORIDE; MITOGEN ACTIVATED PROTEIN KINASE; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; SOMATOMEDIN BINDING PROTEIN 4; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DNA MICROARRAY; DOWN REGULATION; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNINDEXED SEQUENCE; UPREGULATION;

MUS;

EID: 84876665625     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-022-01270-z     Document Type: Erratum

References (72)

1. Arraf Z, Amit T et al (2012) Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease. Neurosci Lett 516(1):57-61
2. Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev 2:325-332
3. Cade JF (2000) Lithium salts in the treatment of psychotic excitement. 1949. Bull World Health Organ 78(4):518-520
4. Campbell S, MacQueen G (2006) An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 19(1):25-33
5. Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96(15):8745-8750
6. Chen RW, Chuang DM (1999) Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 274(10):6039-6042
7. Chen G, Yuan P-X et al (1998) Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem 70(4):1768-1771
8. Chen G, Zeng WZ et al (1999) The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72(2):879-882
9. Chen G, Rajkowska G et al (2000) Enhancement of hippocampal neurogenesis by lithium. J Neurochem 75(4):1729-1734
10. Chiu CT, Chuang DM (2010) Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128(2):281-304
11. Chuang DM (2004) Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 16(1-2):83-90
12. Chuang DM, Chen RW et al (2002) Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 4(2):129-136
13. De Sarno P, Li X et al (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43(7):1158-1164
14. Duggan DJ, Bittner M et al (1999) Expression profiling using cDNA microarrays. Nat Genet 21(1 Suppl):10-14
15. Eugenin EA, King JE et al (2007) HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci USA 104(9):3438-3443
16. Ghasemi M, Dehpour AR (2011) The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci 32(7):420-434
17. Ghee M, Baker H et al (1998) AP-1, CREB and CBP transcription factors differentially regulate the tyrosine hydroxylase gene. Brain Res Mol Brain Res 55(1):101-114
18. Goodwin FK, Ghaemi SN (1999) The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe. Aust N Z J Psychiatry 33(Suppl):S54-S64
19. Graves DJ (1999) Powerful tools for genetic analysis come of age. Trends Biotechnol 17(3):127-134
20. Grimes CA, Jope RS (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 78(6):1219-1232
21. Grunblatt E, Mandel S et al (2001) Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J Neurochem 77(1):146-156
22. Hammonds MD, Shim SS et al (2007) Effects of subchronic lithium treatment on levels of BDNF, Bcl-2 and phospho-CREB in the rat hippocampus. Basic Clin Pharmacol Toxicol 100(5):356-359
23. Hantraye P, Brouillet E et al (1996) Inhibition of neuronal nitric oxide synthase prevents MPTP-induced Parkinsonism in baboons. Nat Med 2(9):1017-1021
24. Huang W, Zhao Y et al (2012) Fluoxetine upregulates phosphorylated-AKT and phosphorylated-ERK1/2 proteins in neural stem cells: evidence for a crosstalk between AKT and ERK1/2 pathways. J Mol Neurosci. doi: 10.1007/s12031-012-9822-5
25. Johannessen M, Delghandi MP et al (2004) What turns CREB on? Cell Signal 16(11):1211-1227
26. Jope RS, Williams MB (1994) Lithium and brain signal transduction systems. Biochem Pharmacol 47(3):429-441
27. Karmarkar SW, Bottum KM et al (2011) ERK/MAPK is essential for endogenous neuroprotection in SCN2.2 cells. PLoS ONE 6(8):e23493
28. Kastner A, Herrero MT et al (1994) Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy. Ann Neurol 36(2):206-214
29. Kopnisky KL, Chalecka-Franaszek E et al (2003) Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 116(2):425-435
30. Lagace DC, Eisch AJ (2005) Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant? Psychiatr Clin North Am 28(2):399-414
31. Li JL, Jing ZZ et al (2003) Effects of lithium on the activity of ERK-1/2 signal pathway and expression of Bcl-2 family proteins in the central nervous system in vivo. Hunan Yi Ke Da Xue Xue Bao 28(4):330-334
32. Machado-Vieira R, Manji HK et al (2009) The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 15(5):525-539
33. Manji HK, Lenox RH (1994) Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 16(1):11-28
34. Manji HK, Potter WZ et al (1995) Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 52(7):531-543
35. Manji HK, Moore GJ et al (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61(Suppl 9):82-96
36. Miller JC, Jimenez P et al (2006) Restraint stress influences AP-1 and CREB DNA-binding activity induced by chronic lithium treatment in the rat frontal cortex and hippocampus. Int J Neuropsychopharmacol 10(5):609-619
37. Monkul ES, Nicoletti MA et al (2006) MRI study of thalamus volumes in juvenile patients with bipolar disorder. Depress Anxiety 23(6):347-352
38. Moore GJ, Bebchuk JM et al (2000a) Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychitary 48(1):1-8
39. Moore GJ, Bebchuk JM et al (2000b) Lithium-induced increase in human brain grey matter. Lancet 356(9237):1241-1242
40. Mora A, Sabio G et al (2002) Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell Signal 14(6):557-562
41. Morabito MA, Sheng M et al (2004) Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons. J Neurosci 24(4):865-876
42. Munoz-Montano JR, Moreno FJ et al (1997) Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 411(2-3):183-188
43. Nadon R, Shoemaker J (2002) Statistical issues with microarrays: processing and analysis. Trends Genet 18(5):265-271
44. Nguyen TB, Manova K et al (2002) Characterization and expression of mammalian cyclin b3, a prepachytene meiotic cyclin. J Biol Chem 277(44):41960-41969
45. Nonaka S, Chuang DM (1998) Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. NeuroReport 9(9):2081-2084
46. Nonaka S, Hough CJ et al (1998) Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-d-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 95(5):2642-2647
47. Offen D, Beart PM et al (1998) Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA 95(10):5789-5794
48. Pardo R, Andreolotti AG et al (2003) Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem 87(2):417-426
49. Perez M, Hernandez F et al (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5(4):301-308
50. Piech-Dumas KM, Tank AW (1999) CREB mediates the cAMP-responsiveness of the tyrosine hydroxylase gene: use of an antisense RNA strategy to produce CREB-deficient PC12 cell lines. Brain Res Mol Brain Res 70(2):219-230
51. Przedborski S, Jackson-Lewis V et al (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93(10):4565-4571
52. Przedborski S, Jackson-Lewis V et al (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76(5):1265-1274
53. Pugazhenthi S, Nesterova A et al (2000) Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275(15):10761-10766
54. Quackenbush J (2006) Computational approaches to analysis of DNA microarray data. Methods Inf Med 45(Suppl 1):91-103
55. Ryves WJ, Harwood AJ (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res 280:720-725
56. Satoh T, Nakatsuka D et al (2000) Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 288(2):163-166
57. Sattler R, Charlton MP et al (1998) Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem 71(6):2349-2364
58. Schulz JB, Matthews RT et al (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 64(2):936-939
59. Shah P, Nankova BB et al (2006) Short chain fatty acids induce TH gene expression via ERK-dependent phosphorylation of CREB protein. Brain Res 1107(1):13-23
60. Sheline YI (2003) Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 54(3):338-352
61. Soares JC, Mann JJ (1997) The anatomy of mood disorders - review of structural neuroimaging studies. Biol Psychiatry 41(1):86-106
62. Valdes JJ, Weeks OI (2009) Estradiol and lithium chloride specifically alter NMDA receptor subunit NR1 mRNA and excitotoxicity in primary cultures. Brain Res 1268:1-12
63. Wada A, Yokoo H et al (2005) Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci 99(4):307-321
64. Wei H, Qin ZH et al (2001) Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106(3):603-612
65. Xiang H, Wang J et al (2006) Role of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells. Mol Cell Biol 26(22):8599-8606
66. Xu Z, Cawthon D et al (2005) Selective alterations of transcription factors in MPP+-induced neurotoxicity in PC12 cells. Neurotoxicology 26(4):729-737
67. Yang L, Matthews RT et al (1998) 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 18(20):8145-8152
68. Youdim MB, Arraf Z (2004) Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46(8):1130-1140
69. 2-terminal kinases in vitro and in the CNS in vivo. J Neurochem 73:2299-2309
70. Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12(1):9-18
71. Zhang S, Edelmann L et al (2008) Cdk5 regulates the phosphorylation of tyrosine 1472 NR2B and the surface expression of NMDA receptors. J Neurosci 28(2):415-424
72. Zigova T, Willing AE et al (1999) Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons. Exp Neurol 157:251-258